Rubicon Announces Heat Shock Protein Publication
Category : Fv-Hsp72
Lake Forest, CA (September 16, 2016) – Rubicon Biotechnology, LLC announces the publication of a review article called “Targeted Heat Shock Protein 72 for Cytoprotection” by Dr. Missag Parseghian, Chief Scientific Officer of Rubicon, in the Annals of the New York Academy of Sciences.Dr. Stephen Hobson of Seacoast Scientific, Inc. and Richard Richieri, COO of Rubicon also contributed to the article.
The review article explores the role of heat shock proteins in the cell and its function as a pulmonary cytoprotectant. Administration of Rubicon’s novel fusion protein, Fv-Hsp70, is very promising because it is capable of delivering Hsp72 directly into the damaged cell in a timely manner. Various methods, including small molecule and gene therapy, have been attempted to induce our cells to make Hsp72 in response to cellular stresses with little success, mainly because it takes too long for the cells to ramp up production of heat shock proteins. Administration of Rubicon’s novel fusion protein, Fv-Hsp70, is very promising because it is capable of delivering Hsp72 directly into the damaged tissue in a timely manner.
About Rubicon Biotechnology
Rubicon Biotechnology is a privately held biotechnology company that develops targeted, life-saving technologies in the areas of defense countermeasures, cardiology, neurology and oncology. Rubicon has in-licensed two platform technologies for drug development. The first is “Antibody Mediated Transduction of Heat Shock Proteins into Living Cells” from the Veterans Administration. This technology delivers heat shock protein, a key protein which saves injured cells that suffer hypoxic and oxidative stresses that unfortunately occur following common tissue injuries, such as heart attack, stroke and traumatic brain injury. The second technology, “Modified Non-Internalizing A5 Variants,” licensed from MosaMedix B.V., delivers immunostimulants to tumors in order to enhance the immune system’s ability to fight cancer. With support from several SBIR and CounterACT grants, and in collaboration with major institutions in the U.S., Rubicon is developing these targeted therapies with the goal of improving health outcomes and saving lives.